Argenx
ARGX
#402
Rank
HK$456.33 B
Marketcap
HK$7,256
Share price
-1.73%
Change (1 day)
1.94%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): HK$174.85

According to Argenx 's latest financial reports the company's current EPS (TTM) is HK$175.28. In 2025 the company made an earnings per share (EPS) of HK$165.24 an increase over its 2024 EPS that were of HK$109.12.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$174.855.81%
2025HK$165.2451.44%
2024HK$109.12-369.77%
2023-HK$40.45-60.46%
2022-HK$102.3063.33%
2021-HK$62.63-40.37%
2020-HK$105.04183.47%
2019-HK$37.06123.09%
2018-HK$16.6154.93%
2017-HK$10.7214.07%
2016-HK$9.4013.05%
2015-HK$8.31-36.34%
2014-HK$13.06209.04%
2013-HK$4.23-33.99%
2012-HK$6.40185.59%
2011-HK$2.24